Daniela Califano

9PUBLICATIONS
85CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer geneticsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Dec 19, 2025
CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC.

Daniela Criscuolo, Francesco Merolla, Benedetta Pellegrino

|Nov 26, 2025
Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial Cancer.

Riccardo Vida, Michele Bartoletti, Lucia Lerda

|Aug 21, 2024
KIR2DL2/DL3+NKs and Helios+Tregs in Peripheral Blood Predict Nivolumab Response in Patients with Metastatic Renal Cell Cancer.

Sara Santagata, Anna Maria Trotta, Crescenzo D'Alterio

|Dec 09, 2023
Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay.

Giovanni L Scaglione, Sandro Pignata, Angela Pettinato

|Sep 23, 2022
Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab.

Marina Fabbi, Delfina Costa, Daniela Russo

|Apr 12, 2022
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients.

Crescenzo D'Alterio, Anna Spina, Laura Arenare

Pageof 2

Frequent Collaborators

5 joint publications

Daniela Russo

4 joint publications

Sandro Pignata

3 joint publications

Paolo Chiodini

2 joint publications

Giosuè Scognamiglio